New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase

A new chromatographic method for the enantioseparation and the determination of (−)-trans-paroxetine and (+)-trans-paroxetine has been developed with the aid of amylose ovomucoid-based chiral stationary phase. The method is faster and five times more sensitive than procedures recommended previously:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisowska-Kuźmicz, Małgorzata, Kantor-Boruta, Małgorzata, Jończyk, Anna, Jarończyk, Małgorzata, Ocios-Bębenek, Agnieszka, Mazurek, Aleksander P., Chilmonczyk, Zdzisław, Jarosz, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026622/
https://www.ncbi.nlm.nih.gov/pubmed/24408298
http://dx.doi.org/10.1007/s00216-013-7565-y
_version_ 1782316867424092160
author Lisowska-Kuźmicz, Małgorzata
Kantor-Boruta, Małgorzata
Jończyk, Anna
Jarończyk, Małgorzata
Ocios-Bębenek, Agnieszka
Mazurek, Aleksander P.
Chilmonczyk, Zdzisław
Jarosz, Maciej
author_facet Lisowska-Kuźmicz, Małgorzata
Kantor-Boruta, Małgorzata
Jończyk, Anna
Jarończyk, Małgorzata
Ocios-Bębenek, Agnieszka
Mazurek, Aleksander P.
Chilmonczyk, Zdzisław
Jarosz, Maciej
author_sort Lisowska-Kuźmicz, Małgorzata
collection PubMed
description A new chromatographic method for the enantioseparation and the determination of (−)-trans-paroxetine and (+)-trans-paroxetine has been developed with the aid of amylose ovomucoid-based chiral stationary phase. The method is faster and five times more sensitive than procedures recommended previously: limit of detection and limit of quantification are 5 and 16 ng/mL, respectively [modified (Ferretti et al. in J Chromatogr B 710:157–164, 1998): 20 and 60 ng/mL]. It was carefully validated and applied for the determination of (−)-trans-paroxetine and (+)-trans-paroxetine in Parogen (Mc Dermott Laboratories Ltd.) and Xetanor (Actavis) coated tablets. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00216-013-7565-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4026622
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-40266222014-05-22 New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase Lisowska-Kuźmicz, Małgorzata Kantor-Boruta, Małgorzata Jończyk, Anna Jarończyk, Małgorzata Ocios-Bębenek, Agnieszka Mazurek, Aleksander P. Chilmonczyk, Zdzisław Jarosz, Maciej Anal Bioanal Chem Note A new chromatographic method for the enantioseparation and the determination of (−)-trans-paroxetine and (+)-trans-paroxetine has been developed with the aid of amylose ovomucoid-based chiral stationary phase. The method is faster and five times more sensitive than procedures recommended previously: limit of detection and limit of quantification are 5 and 16 ng/mL, respectively [modified (Ferretti et al. in J Chromatogr B 710:157–164, 1998): 20 and 60 ng/mL]. It was carefully validated and applied for the determination of (−)-trans-paroxetine and (+)-trans-paroxetine in Parogen (Mc Dermott Laboratories Ltd.) and Xetanor (Actavis) coated tablets. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00216-013-7565-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-01-10 2014 /pmc/articles/PMC4026622/ /pubmed/24408298 http://dx.doi.org/10.1007/s00216-013-7565-y Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Note
Lisowska-Kuźmicz, Małgorzata
Kantor-Boruta, Małgorzata
Jończyk, Anna
Jarończyk, Małgorzata
Ocios-Bębenek, Agnieszka
Mazurek, Aleksander P.
Chilmonczyk, Zdzisław
Jarosz, Maciej
New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title_full New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title_fullStr New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title_full_unstemmed New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title_short New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
title_sort new validated hplc methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase
topic Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026622/
https://www.ncbi.nlm.nih.gov/pubmed/24408298
http://dx.doi.org/10.1007/s00216-013-7565-y
work_keys_str_mv AT lisowskakuzmiczmałgorzata newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT kantorborutamałgorzata newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT jonczykanna newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT jaronczykmałgorzata newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT ociosbebenekagnieszka newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT mazurekaleksanderp newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT chilmonczykzdzisław newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase
AT jaroszmaciej newvalidatedhplcmethodologyforthedeterminationoftransparoxetineanditsenantiomerinpharmaceuticalformulationswithuseofovomucoidchiralstationaryphase

Ejemplares similares